Charles River Laboratories Intl (CRL)
NYSE:CRL
Holding CRL?
Track your performance easily

Charles River Labs (CRL) Stock Forecast & Price Target

514 Followers
See the Price Targets and Ratings of:

CRL Analyst Ratings

Hold
13Ratings
3 Buy
8 Hold
2 Sell
Based on 13 analysts giving stock ratings to
Charles
River Labs
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRL Stock 12 Month Forecast

Average Price Target

$205.00
▼(-4.30% Downside)
Based on 13 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $205.00 with a high forecast of $250.00 and a low forecast of $151.00. The average price target represents a -4.30% change from the last price of $214.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"150":"$150","265":"$265","178.75":"$178.8","207.5":"$207.5","236.25":"$236.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$250.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$205.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":151,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$151.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[150,178.75,207.5,236.25,265],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,180.96,186.27076923076925,191.58153846153846,196.8923076923077,202.20307692307694,207.51384615384615,212.82461538461538,218.13538461538462,223.44615384615383,228.75692307692307,234.0676923076923,239.37846153846152,244.68923076923076,{"y":250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,180.96,182.80923076923077,184.65846153846155,186.5076923076923,188.3569230769231,190.20615384615385,192.0553846153846,193.9046153846154,195.75384615384615,197.6030769230769,199.4523076923077,201.30153846153846,203.15076923076924,{"y":205,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,180.96,178.65538461538463,176.35076923076923,174.04615384615386,171.74153846153845,169.43692307692308,167.1323076923077,164.8276923076923,162.52307692307693,160.21846153846155,157.91384615384615,155.60923076923078,153.30461538461537,{"y":151,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":181.91,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.68,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.89,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.17,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.38,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.1,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.47,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.79,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.66,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.6,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.96,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.74,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":180.96,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$250.00Average Price Target$205.00Lowest Price Target$151.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs
$290$250
Buy
16.71%
Upside
Reiterated
08/07/24
Charles River price target lowered to $250 from $290 at Goldman SachsCharles River price target lowered to $250 from $290 at Goldman Sachs
Deutsche Bank
$300$240
Buy
12.04%
Upside
Assigned
08/07/24
Charles River price target lowered to $240 from $300 at Deutsche BankCharles River price target lowered to $240 from $300 at Deutsche Bank
Argus Research
Hold
Downgraded
06/28/24
Charles River downgraded to Hold from Buy at ArgusCharles River downgraded to Hold from Buy at Argus
Jefferies
$235$226
Hold
5.51%
Upside
Assigned
05/09/24
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL), Plus Therapeutics (NASDAQ: PSTV) and Argenx Se (NASDAQ: ARGX)
UBS
$270$290
Buy
35.39%
Upside
Reiterated
02/15/24
Charles River price target raised to $290 from $270 at UBSCharles River price target raised to $290 from $270 at UBS

Best Analysts Covering Charles River Labs

Which Analyst Should I Follow If I Want to Buy CRL and Sell After:
1 Month
xxx
Success Rate
9/12 ratings generated profit
75%
Average Return
+2.32%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +2.32% per trade.
3 Months
xxx
Success Rate
8/12 ratings generated profit
67%
Average Return
+10.70%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.70% per trade.
1 Year
Success Rate
8/12 ratings generated profit
67%
Average Return
+43.44%
reiterated a buy rating 9 months ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +43.44% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+15.92%
downgraded a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +15.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRL Analyst Recommendation Trends

Rating
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
0
0
0
0
0
Buy
7
7
8
7
5
Hold
7
6
10
8
12
Sell
0
0
0
0
3
Strong Sell
0
0
0
0
0
total
14
13
18
15
20
In the current month, CRL has received 5 Buy Ratings, 12 Hold Ratings, and 3 Sell Ratings. CRL average Analyst price target in the past 3 months is $205.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

CRL Financial Forecast

CRL Earnings Forecast

Next quarter’s earnings estimate for CRL is $2.53 with a range of $2.42 to $2.65. The previous quarter’s EPS was $2.59. CRL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.76% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.
Next quarter’s earnings estimate for CRL is $2.53 with a range of $2.42 to $2.65. The previous quarter’s EPS was $2.59. CRL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.76% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.

CRL Sales Forecast

Next quarter’s sales forecast for CRL is $983.54M with a range of $970.37M to $1.00B. The previous quarter’s sales results were ―. CRL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.45% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.
Next quarter’s sales forecast for CRL is $983.54M with a range of $970.37M to $1.00B. The previous quarter’s sales results were ―. CRL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.45% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.

CRL Stock Forecast FAQ

What is CRL’s average 12-month price target, according to analysts?
Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is $205.00.
    What is CRL’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CRL, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is CRL a Buy, Sell or Hold?
        Charles River Laboratories Intl has a consensus rating of Hold which is based on 3 buy ratings, 8 hold ratings and 2 sell ratings.
          What is Charles River Laboratories Intl’s price target?
          The average price target for Charles River Laboratories Intl is $205.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $250.00 ,the lowest forecast is $151.00. The average price target represents -4.30% Decrease from the current price of $214.2.
            What do analysts say about Charles River Laboratories Intl?
            Charles River Laboratories Intl’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of CRL?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis